Jon Hamilton For the first time, the U.S. military is speaking publicly about what it's doing to address potential health risks to troops who operate certain powerful shoulder-mounted weapons. These bazooka-like weapons produce forceful explosions just inches from the operator's head. Though several scientific reports over the past year have noted the possible risk, until now military officials have been reluctant to speak publicly about whether repeated exposure to these blasts might result in injury to a shooter's brain. Tracie Lattimore, who directs the Army's traumatic brain injury program, agreed to an interview with NPR to talk about steps the military is taking. "We are leaning in and trying to do everything in our power to protect soldiers and service members while they continue to get their job done," says Lattimore, who works in the Office of the Army Surgeon General. She describes a wide-ranging effort that's already begun and includes scientific research on troops' exposure to blast during weapons training, enforcing limits on the firing of certain weapons, and even looking into whether special helmets could help stop blast waves. The Army also has plans to monitor service members' total blast exposure during their military careers, Lattimore says. And even as the Army starts to take preventive measures, some basic questions still need answers. © 2018 npr

Keyword: Brain Injury/Concussion
Link ID: 24998 - Posted: 05.19.2018

Nicola Davis The proportion of young people using marijuana as their first drug doubled in the 10 years from 2004, a US-based study has found. The government study reveals that among people aged between 12 and 21, the proportion of those who tried cigarettes as their first drug fell from about 21% to just under 9% between 2004 and 2014. However, the proportion who turned first to marijuana almost doubled from 4.4% to 8%. While some studies have suggested that, overall, use and abuse of marijuana has fallen among teenagers in the US, the latest research sought to look at trends in which drug, if any, young people turned to first. “We have, particularly in the US, done prevention programmes that are really focused on alcohol and tobacco – and they are relatively easy arguments to make to young people,” said Dr Renee Johnson, a co-author of the study from Johns Hopkins Bloomberg School of Public Health. But she said the “fear factor” is less likely to work for marijuana, noting that public programmes need instead to educate young people so they can make good decisions around drugs, and offer support to help them cope with difficulties in life and think about their life plans. “Once we teach young people about that, that will address the unhealthy marijuana use,” she said. The study, published in the journal Prevention Science, is based on an analysis of data from more than 275,000 participants aged between 12 and 21 collected as part of the US national survey on drug use and health – an annual study that involves participants across all 50 states who are interviewed in person. © 2018 Guardian News and Media Limited

Keyword: Drug Abuse
Link ID: 24997 - Posted: 05.19.2018

By Emily Underwood *Update, 18 May, 10 a.m.: Yesterday, the U.S. Food and Drug Administration approved the first in a new class of drugs designed to prevent migraines. This feature, originally published on 7 January 2016, describes the history of these drugs, the powerful relief they can bring some patients, and the limitations that still exist with them. As long as she can remember, 53-year-old Rosa Sundquist has tallied the number of days per month when her head explodes with pain. The migraines started in childhood and have gotten worse as she’s grown older. Since 2008, they have incapacitated her at least 15 days per month, year-round. Head-splitting pain isn’t the worst of Sundquist’s symptoms. Nausea, vomiting, and an intense sensitivity to light, sound, and smell make it impossible for her to work—she used to be an office manager—or often even to leave her light-proofed home in Dumfries, Virginia. On the rare occasions when she does go out to dinner or a movie with her husband and two college-aged children, she wears sunglasses and noise-canceling headphones. A short trip to the grocery store can turn into a full-blown attack “on a dime,” she says. Every 10 weeks, Sundquist gets 32 bee sting–like injections of the nerve-numbing botulism toxin into her face and neck. She also visits a neurologist in Philadelphia, Pennsylvania, who gives her a continuous intravenous infusion of the anesthetic lidocaine over 7 days. The lidocaine makes Sundquist hallucinate, but it can reduce her attacks, she says—she recently counted 20 migraine days per month instead of 30. Sundquist can also sometimes ward off an attack with triptans, the only drugs specifically designed to interrupt migraines after they start. © 2018 American Association for the Advancement of Science.

Keyword: Pain & Touch
Link ID: 24996 - Posted: 05.19.2018

by Joel Achenbach The National Institutes of Health has ordered a halt to a $100 million, 10-year study of moderate drinking that’s being funded in large part by the alcoholic-beverage industry. Thursday morning’s announcement by NIH Director Francis Collins reflects the seriousness of allegations that surfaced in news reports in recent months, including a story in March in the New York Times that described two scientists and a federal health official pitching the idea for the study to liquor company executives at a 2014 gathering in Palm Beach, Fla. The alcohol industry agreed to fund the research via a private foundation that supports NIH. The goal of the study, which involves 7,000 individuals, is to assess whether moderate drinking — a single drink a day — has a health benefit. Some research has suggested such a benefit, but the conclusion remains controversial, and the U.S. dietary guidelines recommend that people who do not drink alcohol should not start. The Moderate Alcohol and Cardiovascular Health (MACH) trial is based at Harvard’s Beth Israel Deaconess Medical Center, a grantee of the National Institute on Alcohol Abuse and Alcoholism. Collins has ordered two reviews of the study. The first, by the Office of Management Assessment, will “determine if any process or conduct irregularities occurred with grants associated with the MACH Trial,” according to NIH. The second review, by an advisory committee to Collins, will examine the scientific merit of the study. “NIH has requested that the grantee, Beth Israel Deaconess Medical Center, pause all study activities until the reviews are completed,” NIH said in a brief announcement that gave no further details on the reasons for the pause. NIH said Thursday that the reviews are expected to be concluded in June. © 1996-2018 The Washington Post

Keyword: Drug Abuse
Link ID: 24995 - Posted: 05.18.2018

By Gina Kolata The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a device similar to an insulin pen. The list price will be $6,900 a year, and Amgen said the drug will be available to patients within a week. Aimovig blocks a protein fragment, CGRP, that instigates and perpetuates migraines. Three other companies — Lilly, Teva and Alder — have similar medicines in the final stages of study or awaiting F.D.A. approval. “The drugs will have a huge impact,” said Dr. Amaal Starling, a neurologist and migraine specialist at the Mayo Clinic in Phoenix. “This is really an amazing time for my patient population and for general neurologists treating patients with migraine.” Millions of people experience severe migraines so often that they are disabled and in despair. These drugs do not prevent all migraine attacks, but can make them less severe and can reduce their frequency by 50 percent or more. As a recent editorial in the journal JAMA put it, they are “progress, but not a panacea.” Until now, drugs used to prevent migraines were designed to treat other diseases, like high blood pressure. They are not very effective, may work only temporarily, and often are laden with intolerable side effects. In clinical trials, people taking the new drugs reported no more side effects than those taking a placebo. The side effects over the long term and among people with chronic diseases remain to be determined. © 2018 The New York Times Company

Keyword: Pain & Touch
Link ID: 24994 - Posted: 05.18.2018

By Ruth Williams | The sun’s ultraviolet (UV) radiation is a major cause of skin cancer, but it offers some health benefits too, such as boosting production of essential vitamin D and improving mood. Today (May 17), a report in Cell adds enhanced learning and memory to UV’s unexpected benefits. Researchers have discovered that, in mice, exposure to UV light activates a molecular pathway that increases production of the brain chemical glutamate, heightening the animals’ ability to learn and remember. “The subject is of strong interest, because it provides additional support for the recently proposed theory of ultraviolet light’s regulation of the brain and central neuroendocrine system,” dermatologist Andrzej Slominski of the University of Alabama who was not involved in the research writes in an email to The Scientist. “It’s an interesting and timely paper investigating the skin-brain connection,” notes skin scientist Martin Steinhoff of University College Dublin’s Center for Biomedical Engineering who also did not participate in the research. “The authors make an interesting observation linking moderate UV exposure to . . . [production of] the molecule urocanic acid. They hypothesize that this molecule enters the brain, activates glutaminergic neurons through glutamate release, and that memory and learning are increased.” While the work is “fascinating, very meticulous, and extremely detailed,” says dermatologist David Fisher of Massachusetts General Hospital and Harvard Medical School, “it does not imply that UV is actually good for you. . . . Across the board, for humanity, UV really is dangerous.” © 1986-2018 The Scientist

Keyword: Intelligence; Vision
Link ID: 24993 - Posted: 05.18.2018

By Abby Olena The gut-brain axis is line of communication between the two organs, involved in everything from brain development to the progression of neurological diseases, with gut microbiota often pitching in to the conversation. In a study published today (May 16) in Nature, researchers present evidence that multiple sclerosis (MS) may also be influenced by commensal microbes in the gut acting upon cells in the brain. They show in a mouse model of the disease that metabolites from gut bacteria alter the behavior of microglia—immune cells that reside in the brain—which in turn regulate the activity of astrocytes to promote or prevent inflammation. The authors also found evidence in vitro and in patient samples that a similar gut-brain connection exists in people with MS, suggesting that microbes and the cells that receive their signals could be targets for disease treatment. “The beauty of this paper is that it provides a very detailed mechanistic understanding of how things work,” Jonathan Kipnis, a neuroscientist at the University of Virginia who did not participate in the study, tells The Scientist. Previous research linked the microbiome and the development of MS in mice, he says, but “we never understood how the gut communicates with the brain.” In work published in Nature Medicine in 2016, Francisco Quintana of Brigham and Women’s Hospital in Boston and colleagues found part of the answer to the question of gut-brain communication. In that study, they showed that mouse and human astrocytes—star-shape glial cells—respond to molecules generated by microbes from the intestine. And because prior work from other groups had demonstrated that microglia can regulate astrocyte behavior, Quintana says, “one of the biggest unanswered questions we had is: what mediates the crosstalk between microglia and astrocytes?” © 1986-2018 The Scientist

Keyword: Multiple Sclerosis; Glia
Link ID: 24992 - Posted: 05.18.2018

Prion diseases are slow degenerative brain diseases that occur in people and various other mammals. No vaccines or treatments are available, and these diseases are almost always fatal. Scientists have found little evidence of a protective immune response to prion infections. Further, microglia — brain cells usually involved in the first level of host defense against infections of the brain — have been thought to worsen these diseases by secreting toxic molecules that can damage nerve cells. Now, scientists have used an experimental drug, PLX5622, to test the role of microglia against scrapie, a prion disease of sheep. PLX5622 rapidly kills most of the microglia in the brain. When researchers gave the drug to mice infected with scrapie, microglia were eliminated and the mice died one month faster than did untreated mice. The results, published in the Journal of Virology by researchers from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, suggest that microglia can defend against a prion infection and thus slow the course of disease. The scientists hypothesize that microglia trap and destroy the aggregated prion proteins that cause brain damage. The findings suggest that drugs that increase the helpful activity of microglia may have a role in slowing the progression of prion diseases. Researchers are now studying the details of how microglia may be able to destroy prions in the brain. The scientists note that microglia could have a similar beneficial effect on other neurodegenerative diseases associated with protein aggregation, such as Alzheimer’s disease and Parkinson’s disease.

Keyword: Prions; Glia
Link ID: 24991 - Posted: 05.18.2018

By Diana Kwon When Eliza O’Neill was 3 years old, her parents, Glenn and Cara, noted that her development began to diverge from that of her peers. Their once fast-learning, gregarious child faced difficulties in school, and her improvements in areas such as social communication and speech began to slow. It took about six months and multiple visits to the doctor for Eliza to be diagnosed with Sanfilippo syndrome, a rare lysosomal storage disease in which sugar molecules called glycosaminoglycans build up in the central nervous system, destroying cells and eventually causing severe dementia, seizures, and a loss of mobility. The disease strikes between 1 and 9 out of 1,000,000 people, and most children affected do not survive beyond their teens. The diagnosis, which Eliza’s doctors made in July 2013, was like “a lightning bolt out of the sky,” Glenn recalls. “I didn’t even know that a disease as terrible as this could even exist.” In the weeks following Eliza’s diagnosis, the O’Neills combed the scientific literature looking for a way to save their daughter. Their research led them to a potential gene therapy for Sanfilippo under investigation at Nationwide Children’s Hospital (NCH) in Columbus, Ohio. At the time, the work was still in the preclinical stage, but “the data were amazing,” says Cara, a pediatrician. Once she found this study, she contacted Haiyan Fu, a scientist at NCH’s Center for Gene Therapy working on the experiments, who walked her through the research. “That was the first moment that I had a real solid hope in the science,” Cara recalls. © 1986-2018 The Scientist

Keyword: Development of the Brain
Link ID: 24990 - Posted: 05.18.2018

By Simon Baron-Cohen, The Austrian paediatrician Hans Asperger has long been recognized as a pioneer in the study of autism. He was even seen as a hero, saving children with the condition from the Nazi killing programme by emphasizing their intelligence. However, it is now indisputable that Asperger collaborated in the murder of children with disabilities under the Third Reich. Historian Herwig Czech fully documented this in the April 2018 issue of Molecular Autism (a journal I co-edit; see H. Czech Mol. Autism 9, 29; 2018). Now, historian Edith Sheffer’s remarkable book Asperger’s Children builds on Czech’s study with her own original scholarship. She makes a compelling case that the foundational ideas of autism emerged in a society that strove for the opposite of neurodiversity. Advertisement These findings cast a shadow on the history of autism, already a long struggle towards accurate diagnosis, societal acceptance and support. The revelations are also causing debate among autistic people, their families, researchers and clinicians over whether the diagnostic label of Asperger’s syndrome should be abandoned. In 1981, psychiatrist Lorna Wing published the paper in Psychological Medicine that first brought Asperger’s clinical observations to the attention of the English-speaking medical world, and coined the term Asperger’s syndrome (L. Wing Psychol. Med. 11, 115–129; 1981). A decade later, in the book Autism and Asperger Syndrome (1991), developmental psychologist Uta Frith translated into English the 1944 treatise by Asperger in which he claimed to have discovered autism. © 2018 Scientific American

Keyword: Autism
Link ID: 24989 - Posted: 05.18.2018

Nicola Davis People who experience disrupted 24-hour cycles of rest and activity are more likely to have mood disorders, lower levels of happiness and greater feelings of loneliness, research suggests. While the study does not reveal whether disruptions to circadian rhythms are a cause of mental health problems, a result of them or some mixture of the two, the authors say the findings highlight the importance of how we balance rest and activity. “Because people have these 24-hour patterns of living nowadays and because by 2050 two-thirds of the world’s population will live in cities where circadian disruption is much more likely, it is quite a big public health issue. How do we take account of our natural patterns of rest and activity and how do we design cities or jobs to protect people’s mental health?” said Daniel Smith, professor of psychiatry at the University of Glasgow and lead author of the research. Writing in the journal Lancet Psychiatry, a team of researchers from Scotland, Ireland and Sweden report how they carried out the largest study of its kind to date by harnessing data from the UK BioBank, a research endeavour that has collected health information on 500,000 participants, aged between 37 and 73, since 2006. To explore the link between mental health and the 24-hour cycles of sleep and activity known as circadian rhythms, the team looked at data from more than 91,000 participants who had worn a wrist-based activity tracker for a week at some point between 2013 and 2015. © 2018 Guardian News and Media Limited

Keyword: Biological Rhythms; Depression
Link ID: 24988 - Posted: 05.17.2018

by Ariana Eunjung Cha Women having trouble getting pregnant sometimes try yoga, meditation or mindfulness, and some research suggests that psychological stress may affect infertility. But what about men: Does their mental state affect a couple's ability to conceive? The latest research on this subject was published Thursday in the journal Fertility and Sterility and suggests that a link between mental health and fertility may exist for women and men. The study involved data from 1,650 women and 1,608 men who were recruited through the National Institutes of Health's Reproductive Medicine Network at six sites in the United States. Most of the participants were couples, and they were undergoing some kind of fertility treatment, such as ovarian stimulation medication or artificial insemination, but not in vitro fertilization. Based on a questionnaire, about 6 percent of the women and 2 percent of the men were rated as having major depression. While the number of men with major depression in the analysis was small — just 34 — an analysis found differences between them and the other men in the study. Those with major depression were 60 percent less likely to have a live birth than men who did not have major depression. More specifically, of the 34, only three of the couples, or less than 9 percent, achieved a live birth. That compares with nearly 25 percent having a live birth for couples in which the male partner did not have major depression. © 1996-2018 The Washington Post

Keyword: Depression; Sexual Behavior
Link ID: 24987 - Posted: 05.17.2018

By Jeremy Rehm A man may be attractive because of his curly, blond hair or slick pin-striped suit, but strip everything away and one luring—maybe evolutionary—piece remains, a new study finds: how proportional his body is, especially his legs. Women prefer a man with legs that are about half his height, according to previous research; scientists believe that is an evolutionary result of women wanting to choose only healthy men. Legs that are too short, for example, have been linked to type 2 diabetes. But other proportions, such as arm length to body height or whether the elbow and knee divide a limb in half, can also relate to a person’s health. Do they influence women’s views as well? To answer this, researchers collected average body proportions from roughly 9000 men in the U.S. military and used them to create computer-generated images of male models (pictured). The scientists made the model’s arms and legs slightly longer or shorter, and then asked more than 800 heterosexual U.S. women to rank each model’s attractiveness. © 2018 American Association for the Advancement of Science.

Keyword: Sexual Behavior; Evolution
Link ID: 24986 - Posted: 05.17.2018

By Abdul-Kareem Ahmed “Dad, hold still.” As we entered the hospital room that morning, our patient’s daughter was attempting to give him a shave. He was bed-bound after his operation and had grown a salt-and-pepper stubble. A week earlier, his wife had brought him to the emergency room . He was behaving oddly, mumbling nonsensical sentences and stumbling through the house. Sixty-two years old, male, Caucasian, new and profound neurological symptoms. An M.R.I. of his brain seemed redundant but confirmed the diagnosis: A four-centimeter malignant tumor was invading his right frontal cortex, the seat of his personality, where “Dad” lived. I’m drawn to the human brain, its unforgiving and protean nature. Just five minutes without oxygen, and the brain loses function. The occipital cortex processes visual information and allows us to see faces, trees, the stars. However, in a young child who becomes blind, as with Helen Keller, this same cortex can be repurposed for entirely distinct functions, like language processing. Early astronomers looked to the heavens for answers. But in the human brain, a three-pound ball of fat, there resides enough mystery and potential to have satisfied Galileo, Kepler and Brahe. And so I found myself, on what had now been a four-year foray toward a career in neurosurgery, helping care for this patient. I was the sub-intern at a hospital away from home for the month. It was my first week on the job. The resident and I stood around his bed in our cerulean scrubs and white coats and watched him smiling. His daughter looked toward me, the only other male in the room, and paused, razor in hand. © 2018 The New York Times Company

Keyword: Emotions
Link ID: 24985 - Posted: 05.17.2018

By Shawn Hayward Brenda Milner has collected her share of awards, prizes, honourary degrees and other recognitions throughout her amazing career, but there is something special about being recognized with top honours from the city and province she has called home since 1944, all within one week. On May 8, the Speaker of the National Assembly of Quebec, Jacques Chagnon presented Milner with its Medal of Honour, along with seven other Quebecers including McGill alumna Dr. Joanne Liu. The Medal of Honour is awarded to public figures from all walks of life who, through their career, their work or their social commitment, have earned the recognition of the Members of the National Assembly and the people of Quebec. Milner added to that recognition the title of Commander of the Order of Montreal, given to her by Mayor Valérie Plante during a ceremony at City Hall on May 14. The Order of Montreal was created on the city’s 375th anniversary to recognize women and men who have contributed in a remarkable way to the city’s development and reputation. There are three ranks in the Order, Commander being the highest. A celebrated researcher at the Montreal Neurological Institute and Hospital (The Neuro), Milner turns 100 years old on July 15. She is the Dorothy J. Killam Professor at The Neuro, and a professor in the Department of Neurology and Neurosurgery at McGill University. © 2018 McGill Reporter ·

Keyword: Learning & Memory
Link ID: 24984 - Posted: 05.17.2018

By Maya Salam Three years ago, the internet melted down over the color of a dress. Now an audio file has friends, family members and office mates questioning one another’s hearing, and their own. Is the robot voice saying “Yanny” or “Laurel”? The clip picked up steam after a debate erupted on Reddit this week, and it has since been circulated widely on social media. One Reddit user said: “I hear Laurel and everyone is a liar.” “They are saying they hear ‘Yanny’ because they want attention,” a tweet read. Others claimed they heard one word for a while, then the other — or even both simultaneously. It didn’t take long for the auditory illusion to be referred to as “black magic.” And more than one person online yearned for that simpler time in 2015, when no one could decide whether the mother of the bride wore white and gold or blue and black. It was a social media frenzy in which internet trends and traffic on the topic spiked so high that Wikipedia itself now has a simple entry, “The dress.” Of course, in the grand tradition of internet reportage, we turned to a scientist to make this article legitimately newsworthy. Dr. Jody Kreiman, a principal investigator at the voice perception laboratory at the University of California, Los Angeles, helpfully guessed on Tuesday afternoon that “the acoustic patterns for the utterance are midway between those for the two words.” “The energy concentrations for Ya are similar to those for La,” she said. “N is similar to r; I is close to l.” She cautioned, though, that more analysis would be required to sort out the discrepancy. That did not stop online sleuths from trying to find the answer by manipulating the bass, pitch or volume. © 2018 The New York Times Company

Keyword: Hearing; Attention
Link ID: 24983 - Posted: 05.16.2018

By Shawna Williams Even as patients with Parkinson’s disease, obsessive-compulsive disorder, and other conditions turn to deep brain stimulation (DBS) to keep their symptoms in check, it’s been unclear to scientists why the therapy works. Now, researchers in Texas report that in mice, the treatment dials the activity of hundreds of genes up or down in brain cells. Their results, published in eLife March 23, hint that DBS’s use could be expanded to include improving learning and memory in people with intellectual disabilities. “The paper is very well done. . . . It’s really a rigorous study,” says Zhaolan “Joe” Zhou, a neuroscientist at the University of Pennsylvania’s Perelman School of Medicine who reviewed the paper for eLife. Now that the genes and pathways DBS affects are known, researchers can home in on ways to improve the treatment, or perhaps combine the therapy with pharmacological approaches to boost its effect, he says. In DBS, two electrodes are surgically implanted in a patient’s brain (the area depends on the disorder being treated), and connected to generators that are placed in the chest. Gentle pulses of electricity are then passed continuously through the electrodes. The treatment reduces motor symptoms in many people with Parkinson’s, and allows some patients to reduce their use of medications, but it does not eliminate symptoms or slow the disease’s progression. In addition to its use in movement disorders, DBS is being explored as a potential therapy for a range of other brain-related disorders. For instance, as a way to boost learning and memory in people with Alzheimer’s disease, researchers are looking into stimulating the fimbria-fornix, a brain region thought to regulate the activity of the memory-storing hippocampus. © 1986-2018 The Scientist

Keyword: Parkinsons; Epigenetics
Link ID: 24982 - Posted: 05.16.2018

Richard Harris Children and adolescents are getting fewer prescription drugs than they did in years past, according to a study that looks at a cross-section of the American population. "The decrease in antibiotic use is really what's driving this overall decline in prescription medication use that we're seeing in children and adolescents," says Craig Hales, a preventive medicine physician at the Centers for Disease Control and Prevention's National Center for Health Statistics and lead author of a study published Tuesday in JAMA. Hales says that's a good thing. "Thirty percent of antibiotic prescriptions are unnecessary and potentially dangerous," he says. They're often given for colds and other viral infections, where they are useless. And they may have side effects. Antibiotic overuse also increases the risk that these drugs lose their curative powers. The study is based on data from the National Health and Nutrition Examination Study, which included more than 38,000 children and adolescents. The study compared prescription drug use from 1999 to 2002 with prescriptions given in 2011 to 2014, the last period for which data were available. Overall, the proportion of children and teenagers getting prescriptions dropped from about 25 percent to 22 percent. Prescriptions for some drugs increased, such as for treatments for asthma, contraception and attention-deficit and hyperactivity disorder (ADHD). The survey also noted a large gap in prescription use among children and adolescents who were insured versus those who weren't. Some 23 percent of insured youth had recently taken a prescription of some sort, compared with 10 percent of those who were uninsured. © 2018 npr

Keyword: ADHD; Drug Abuse
Link ID: 24981 - Posted: 05.16.2018

by Eli Rosenberg In what is believed to be one of the first deaths from an e-cigarette explosion, a 38-year-old man in Florida was killed when his vape pen exploded, sending projectiles into his head and causing a small fire in his house. Tallmadge D’Elia was found May 5 in the burning bedroom of his family’s home in St. Petersburg, according to the Tampa Bay Times. An autopsy report released his week blamed a vape pen explosion for his death, local news outlets reported. The cause of death was listed as “projectile wound of head” — the pen exploded into pieces, at least two of which were sent into his head, the Pinellas-Pasco Medical Examiner said — and he suffered burns on about 80 percent of his body. The “mod”-type pen, distributed by Smok-E Mountain, is manufactured in the Philippines, according to a company Facebook page, the Times reported. The Facebook page is not currently publicly accessible. According to a report from the U.S. Fire Administration, which is part of the Federal Emergency Management Agency, there were at least 195 incidents in which an electronic cigarette exploded or caught fire from 2009 through 2016, resulting in 133 injuries, 38 of which were severe. But there were no recorded deaths in the study's period. The explosions usually occur suddenly, the report found, “and are accompanied by loud noise, a flash of light, smoke, flames, and often vigorous ejection of the battery and other parts.” © 1996-2018 The Washington Post

Keyword: Drug Abuse
Link ID: 24980 - Posted: 05.16.2018

By Usha Lee McFarling, STAT UCLA neuroscientists reported Monday that they have transferred a memory from one animal to another via injections of RNA, a startling result that challenges the widely held view of where and how memories are stored in the brain. The finding from the lab of David Glanzman hints at the potential for new RNA-based treatments to one day restore lost memories and, if correct, could shake up the field of memory and learning. “It’s pretty shocking,” said Dr. Todd Sacktor, a neurologist and memory researcher at SUNY Downstate Medical Center in Brooklyn, N.Y. “The big picture is we’re working out the basic alphabet of how memories are stored for the first time.” He was not involved in the research, which was published in eNeuro, the online journal of the Society for Neuroscience. Advertisement Many scientists are expected to view the research more cautiously. The work is in snails, animals that have proven a powerful model organism for neuroscience but whose simple brains work far differently than those of humans. The experiments will need to be replicated, including in animals with more complex brains. And the results fly in the face of a massive amount of evidence supporting the deeply entrenched idea that memories are stored through changes in the strength of connections, or synapses, between neurons. © 2018 Scientific American

Keyword: Learning & Memory
Link ID: 24979 - Posted: 05.15.2018